Business Insider

New St. Gallen International Breast Cancer Guidelines Recommend Oncotype DX Breast Recurrence Score® Test to Guide Chemotherapy for Node-negative and Node-positive Early-stage ...

REDWOOD CITY, Calif., Aug. 21, 2019 /PRNewswire/ -- Genomic Health today announced that, based on results from the prospective TAILORx 1 and PlanB 2 studies, the 16 th St. Gallen International Breast ...
Business Insider

New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment

REDWOOD CITY, Calif., Oct. 9, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score ® test has been categorized as the only "preferred" ...
EurekAlert!

EndoPredict outperforms Oncotype Dx in predicting the risk breast cancer recurrence

Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak, Ph.D. Date: Friday, Dec.9, 2016: 4:15 p.m. CT. Location: S6-05; General Session 6 - ...
Time

Genetic Test Impacts Chemo Choices In Surprising Ways

In the new era of personalized medicine, having more information on hand is considered the ideal situation for making more customized, and ideally, effective decisions about medical care. And in a new ...
Nature

Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores

As FOXA1, GATA3, and ER coexist in a network regulating luminal subtype A breast carcinomas, we hypothesized that tumors expressing FOXA1 and/or GATA3 will have a low recurrence score. We therefore ...
Nature

Crunch time for multiple-gene tests

Sophisticated new genetic tests face an uncertain future — unless they can win clear-cut approval from regulators, insurers and, most importantly, doctors. Virginia Gewin reports. For many of the ...